CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Vertex Pharmaceuticals Incorporated

VRTX
$114.63B
Large Cap
NASDAQPharmaceutical Preparations🇺🇸North AmericaBOSTON6.1K employees
Website

Drugs in Pipeline

61

Phase 3 Programs

32

Upcoming Catalysts

20

Next Catalyst

Aug 3, 2026

5d

Market Overview

Stock performance and key metrics

VRTX News
Catalyst Timeline

20 upcoming, 2 past

EarningsNext

VRTX Earnings Report

Aug 3, 2026

EPS Est: $4.30 | FQ end 2026-06 | Call: 2026-08-03 15:00:00

19 more catalysts beyond 14 days

Start a 48-hour free trial to see all upcoming catalysts

Pro

How VRTX's past catalysts played out

Phase 3 readoutMay 2026+8%earningsFeb 2026+6%earningsAug 2025-21%earningsMay 2025-10%earningsNov 2024+6%earningsOct 2022+9%
Drug Pipeline

Suzetrigine

Phase 3

Pain

Patent 2040

VX-445/TEZ/IVA

Phase 3

Cystic Fibrosis

VX-121/TEZ/D-IVA

Phase 3

Cystic Fibrosis

Povetacicept

Phase 3

Primary Membranous Nephropathy

IVA

Phase 3

Cystic Fibrosis

VX-880

Phase 3

Type 1 Diabetes

OrphanFast TrackBreakthrough

Lumacaftor

Phase 3

Cystic Fibrosis

CTX001

Phase 3

Beta-Thalassemia

VX-661/Ivacaftor

Phase 3

Cystic Fibrosis

Patent 2033

HB/APAP

Phase 3

Acute Pain

Pegylated Interferon Alfa 2a

Phase 3

Chronic Hepatitis C

SUZ

Phase 3

Acute Pain

VX-659/TEZ/IVA

Phase 3

Cystic Fibrosis

Tezacaftor/Ivacaftor

Phase 3

Cystic Fibrosis

ribavirin

Phase 3

Hepatitis C

LUM/IVA

Phase 3

Cystic Fibrosis

Ivacaftor

Phase 3

Cystic Fibrosis

Patent 2033

TEZ

Phase 3

Cystic Fibrosis

TEZ/IVA

Phase 3

Cystic Fibrosis

Biological/Vaccine

Phase 3

Type 1 Diabetes

Casgevy

Exagamglogene Autotemcel

Phase 3

Sickle Cell Disease

OrphanFast TrackBreakthrough

VX-770

Phase 3

Cystic Fibrosis

Suzetrigine (SUZ)

Phase 3

Acute Pain

Pregabalin

Phase 3

Diabetic Peripheral Neuropathic Pain

Patent 2027

LUM

Phase 3

Cystic Fibrosis

VX-509

Phase 3

Rheumatoid Arthritis

VX-809

Phase 3

Cystic Fibrosis

Telaprevir

Phase 3

Hepatitis C

Patent 2028

ELX/TEZ/IVA

Phase 3

Cystic Fibrosis

VX-147

Phase 3

Proteinuric Kidney Disease

VX-661 plus ivacaftor combination

Phase 3

Cystic Fibrosis

Lumacaftor Plus Ivacaftor Combination

Phase 3

Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation

VX-121 (Suspension)

Phase 2

Cystic Fibrosis

VX-661

Phase 2

Cystic Fibrosis

Cethrin

Phase 2

Spinal Cord Injury

VX-150

Phase 2

Osteoarthritis

Ivacaftor 25 mg/75 mg

Phase 2

Cystic Fibrosis

VX-702

Phase 2

Rheumatoid Arthritis

Inaxaplin

Phase 2

Proteinuric Kidney Disease

VX-121

Phase 2

Cystic Fibrosis

VX-787

Phase 2

Influenza Virus

VX-222

Phase 2

Chronic Hepatitis C Virus

VX-993

Phase 2

Acute Pain

VX-950

Phase 2

Hepatitis C

VX-445

Phase 2

Cystic Fibrosis

VX-670

Phase 2

Myotonic Dystrophy Type 1 (DM1)

VX-152

Phase 2

Cystic Fibrosis

VX-765

Phase 2

Partial Epilepsy

VX-659

Phase 2

Cystic Fibrosis

VX-440

Phase 2

Cystic Fibrosis

VX-522 mRNA therapy

Phase 2

Cystic Fibrosis

VX-561

Phase 2

Cystic Fibrosis

VX-864

Phase 2

Alpha1-Antitrypsin Deficiency

VCH-759 (BCH-27759)

Phase 2

Hepatitis C, Chronic

VX-135

Phase 2

Chronic Hepatitis C

Daclatasvir

Phase 2

Chronic Hepatitis C

VX-264

Phase 2

Type 1 Diabetes

Merimepodib

Phase 2

Hepatitis C

VX-407

Phase 2

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

peginterferon alfa-2a

Phase 2

Hepatitis C

VX-548

Phase 2

Acute Pain

Fast Track

Cystic Fibrosis

25 drugs in this indication

Acute Pain

5 drugs in this indication

Hepatitis C

4 drugs in this indication

Proteinuric Kidney Disease

2 drugs in this indication

Type 1 Diabetes

2 drugs in this indication

Rheumatoid Arthritis

2 drugs in this indication

Beta-Thalassemia

1 drug in this indication

Spinal Cord Injury

1 drug in this indication

Pain

1 drug in this indication

Influenza Virus

1 drug in this indication

Primary Membranous Nephropathy

1 drug in this indication

Partial Epilepsy

1 drug in this indication

Osteoarthritis

1 drug in this indication

Chronic Hepatitis C Virus

1 drug in this indication

Myotonic Dystrophy Type 1 (DM1)

1 drug in this indication

Sickle Cell Disease

1 drug in this indication

Chronic Hepatitis C

1 drug in this indication

Diabetic Peripheral Neuropathic Pain

1 drug in this indication

Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

1 drug in this indication

Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation

1 drug in this indication

Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)

📑
Catalyst DossierPRO
The full research note — thesis, the if-approved scenario, financials & smart money. Compiled by CeliA.
→
Catalyst Verdict

Full breakdown — the signals behind the verdict

Market-Implied Move
Regulatory Approvals

Frequently asked questions

What is in Vertex Pharmaceuticals Incorporated's drug pipeline?→

CatalystAlert tracks 61 drug candidates in Vertex Pharmaceuticals Incorporated's (VRTX) pipeline across Phase 3, Phase 2. Its lead program is Suzetrigine (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Vertex Pharmaceuticals Incorporated's next FDA catalyst?→

Vertex Pharmaceuticals Incorporated's (VRTX) next tracked catalyst is a Acquisition expected July 23, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track VRTX biotech catalysts?→

Add VRTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Vertex Pharmaceuticals Incorporated's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply